Does Cosentyx Cause Heart Problems?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, lists major adverse cardiovascular events (MACE) like heart attack, stroke, and cardiovascular death as a potential risk in its prescribing information. This stems from a large clinical trial pooling data from 10 studies (3,430 patients on Cosentyx vs. 1,472 on placebo), where MACE occurred in 0.7% of Cosentyx patients compared to 0.4% on placebo over 52 weeks—mostly in those with cardiovascular risk factors like prior heart disease or diabetes.[1][2]
Why the Heart Risk Warning?
The label warns of increased MACE risk, particularly in patients with a history of serious cardiac conditions or risk factors. Mechanism may tie to IL-17's role in inflammation; blocking it could alter vascular inflammation, though evidence is observational, not causal. FDA approved this warning in 2017 based on post-hoc trial analysis, but no dedicated cardiovascular safety trials exist.[1][3]
How Common Are Heart Issues in Real-World Use?
Post-marketing data and registries show rare reports of heart failure, arrhythmias, and myocardial infarction, but rates align with disease populations (psoriasis patients already have 50% higher cardiovascular risk). A 2023 study in Rheumatology tracked 1,200+ patients; no significant Cosentyx-MACE link after 2 years, though monitoring is advised.[4] Serious events: <1% in trials.
Who Should Worry Most?
Patients over 50, smokers, diabetics, hypertensives, or with prior heart events face higher scrutiny—discontinue if new symptoms arise. No blanket avoidance; benefits often outweigh risks for inflammatory disease control.[1][2]
What Do Doctors Monitor?
Baseline ECG and lipids recommended; watch for chest pain, shortness of breath. No routine cardiac imaging needed unless symptoms. Guidelines (e.g., ACR) urge risk factor management alongside treatment.[3]
Alternatives with Lower Heart Concerns?
| Drug | Heart Risk Profile | Key Difference |
|------|---------------------|---------------|
| Stelara (ustekinumab) | Similar MACE warning, but fewer reports | IL-12/23 inhibitor; less vascular inflammation data |
| Tremfya (guselkumab) | No MACE label; observational safety favorable | IL-23 specific; emerging long-term CV data clean |
| Skyrizi (risankizumab) | Minimal CV signals in trials | IL-23; preferred for high-risk patients per some reviews |
| Methotrexate | Established CV risk (heart failure) | Cheaper oral, but less effective for skin/joints |
Switching depends on disease response; consult rheumatologist.[5]
[1]: Cosentyx Prescribing Information (Novartis, 2023)
[2]: FDA Label for Secukinumab
[3]: Novartis Safety Data
[4]: Rheumatology Journal Study (2023)
[5]: ACR Guidelines on Psoriatic Arthritis (2021)